4D Molecular Therapeutics, Inc. Increase (Decrease) in Accounts Payable
4D Molecular Therapeutics, Inc. (FDMT) reported Increase (Decrease) in Accounts Payable of -$525.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$4.06M, a 189.21% decline year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $3.53M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $4.30M, a 193.84% increase year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.84M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $6.77M, a 677.61% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $871.00K, a 2.79% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $896.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.64M, a 171.68% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$525.00K 10-Q · filed 2026-08-13 | $3.77M derived: sum of 3 quarters · filed 2026-08-13 | $1.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.53M 10-Q · filed 2026-05-07 | $7.83M derived: sum of 2 quarters · filed 2026-05-07 | $5.99M derived: sum of 3 quarters · filed 2026-05-07 | $10.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.46M derived: sum of 2 quarters · filed 2026-03-18 | $7.01M derived: sum of 3 quarters · filed 2026-08-13 | $6.77M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.71M derived: sum of 2 quarters · filed 2026-08-13 | $2.48M 10-Q · filed 2025-11-10 | $3.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.31M 10-Q · filed 2026-08-13 | $5.78M derived: sum of 3 quarters · filed 2026-08-13 | $5.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$235.00K 10-Q · filed 2026-05-07 | $1.23M derived: sum of 2 quarters · filed 2026-05-07 | $719.00K derived: sum of 3 quarters · filed 2026-05-07 | -$67.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $954.00K derived: sum of 2 quarters · filed 2026-03-18 | $168.00K derived: sum of 3 quarters · filed 2026-03-18 | $871.00K 10-K · filed 2026-03-18 |
| 2024-09-30 | -$508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.29M derived: sum of 2 quarters · filed 2025-11-10 | -$591.00K 10-Q · filed 2025-11-10 | -$1.68M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$786.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$83.00K 10-Q · filed 2025-08-11 | -$1.17M derived: sum of 3 quarters · filed 2025-08-11 | $199.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $703.00K 10-Q · filed 2025-05-08 | -$385.00K derived: sum of 2 quarters · filed 2025-05-08 | $985.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.93M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $282.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.23M derived: sum of 3 quarters · filed 2025-02-28 | $896.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.32M derived: sum of 2 quarters · filed 2024-11-13 | $1.98M 10-Q · filed 2024-11-13 | $3.50M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $947.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $614.00K 10-Q · filed 2024-08-08 | $2.13M derived: sum of 3 quarters · filed 2024-08-08 | $430.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$333.00K 10-Q · filed 2024-05-09 | $1.18M derived: sum of 2 quarters · filed 2024-05-09 | -$517.00K derived: sum of 3 quarters · filed 2024-05-09 | -$291.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$184.00K derived: sum of 2 quarters · filed 2024-02-29 | $42.00K derived: sum of 3 quarters · filed 2024-02-29 | -$1.64M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.47M derived: sum of 2 quarters · filed 2023-11-09 | -$3.15M 10-Q · filed 2023-11-09 | -$1.49M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.45M 10-Q · filed 2023-08-09 | $208.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.00M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.68M 10-Q · filed 2023-05-11 | -$18.00K derived: sum of 2 quarters · filed 2023-05-11 | $777.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.21M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.46M derived: sum of 2 quarters · filed 2023-03-15 | $2.89M derived: sum of 3 quarters · filed 2023-03-15 | $2.29M 10-K · filed 2023-03-15 |
| 2021-09-30 | $795.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.22M derived: sum of 2 quarters · filed 2022-11-08 | $623.00K 10-Q · filed 2022-11-08 | $1.19M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$172.00K 10-Q · filed 2022-08-11 | $395.00K derived: sum of 3 quarters · filed 2022-08-11 | -$2.38M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$601.00K 10-Q · filed 2022-05-12 | -$34.00K derived: sum of 2 quarters · filed 2022-05-12 | -$2.81M derived: sum of 3 quarters · filed 2022-05-12 | -$225.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$2.21M derived: sum of 2 quarters · filed 2022-03-28 | $376.00K derived: sum of 3 quarters · filed 2022-03-28 | $43.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$191.00K derived: sum of 2 quarters · filed 2021-11-10 | -$524.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.25M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$333.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $533.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |